Sungate 5 mg/ml 1 ml
Le numéro d’autorisation de mise sur le marché de votre pays ne pas répertorié ? Il s'agit alors d'un produit cascade. Cliquez ici pour plus d'informations.
Regenerative therapy in aseptic joint diseases of the horse, characterized by degeneration of articular cartilage and synovial membrane with altered articular function
Composition
Micronized stanozolol 5 mg/ml
Indicationn
Regenerative therapy in aseptic joint diseases of the horse, characterized by degeneration of articular cartilage and synovial membrane with altered articular function; Also associated with the production of synovial fluid with poor or altered viscoelastic characteristics.
NOTES
Positive clinical effects may present in time-frames that vary according to the stage of evolution and the gravity of the disease. In chronic joint disease, clinical improvement may take place as much as one month after the end of treatment and subsequently consolidate through a slow but constant progression. This latent period can be explained by the time needed for the medicinal product’s regenerative action to take effect. Rehabilitation exercises shorten the time needed for tissue regeneration and the reduction of symptoms.
Dosage
Solution for intraarticular injection. The dosage varies according to the size of the joint to be treated.
Do not exceed recommended doses:
- 1ml of suspension equal to 5 mg of stanozolol in medium-sized joints (e.g. tarsal joint, fetlock) once weekly. Weekly administration can be repeated up to six times, according to the severity and evolutionary stage of the joint disease.
- In smaller joints (the joints of ponies or foals or interphalangeal joints), reduce the dose proportionately to 1.0 – 2.5 mg.